Dynavax Technologies Corp
Change company Symbol lookup
Select an option...
DVAX Dynavax Technologies Corp
GE General Electric Co
GTPBU Gores Technology Partners II Inc
IRBT iRobot Corp
NRG NRG Energy Inc
FRLAU Fortune Rise Acquisition Corp
BTBT Bit Digital Inc
RUMBW Rumble Equity Warrant Exp 16th Sept 2027 *W EXP 09/16/2027
RSLS ReShape Lifesciences Inc
BWA Borgwarner Inc
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company that is focused on developing and commercializing vaccines. The Company's products include HEPLISAV-B and CpG 1018. The HEPLISAV-B is indicated for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. HEPLISAV-B is a sterile solution for injection presented in 0.5 mL single-dose prefilled syringes. The Company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. The Company is also engaged in developing CpG 1018 as a vaccine adjuvant through research collaborations and partnerships. HEPLISAV-B combines 1018, a toll-like receptor (TLR9) agonist adjuvant, and recombinant hepatitis B surface antigen (rHBsAg). It is primarily focused on adjuvanted vaccines for coronavirus disease (COVID-19), plague, Tdap, seasonal influenza, universal influenza, and shingles.

Postmarket

Last Trade
Delayed
$9.90
-0.03 (-0.30%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$9.93
Day's Change
-0.31 (-3.03%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
10.48
Day's Low
9.92
Volume
(Light)
Volume:
1,293,356

10-day average volume:
2,175,675
1,293,356

Moderna's stock rises 3% after beating earnings expectations in the second quarter

7:47 am ET August 3, 2022 (MarketWatch)
Print

Shares of Moderna Inc. (MRNA) gained 3.8% in premarket trading on Wednesday after the company beat earnings and revenue expectations in the second quarter of the year. Moderna had net income of $2.2 billion, or $5.24 per share, in the second quarter of the year, down from $2.8 billion, or $6.46 per share, in the same quarter a year ago. The FactSet consensus was $4.58. Revenue came in at $4.7 billion for the quarter, up from $4.3 billion in the second quarter of last year. The FactSet consensus was $4.1 billion. The company said it expects to deliver $21 billion worth of COVID-19 vaccines and boosters this year. Separately, the biotechnology company set a new $3 billion stock repurchase program, which represents about 4.7% of the company's market capitalization of $63.96 billion as of Tuesday's closing prices. Moderna's stock is down 36.7% so far this year, while the broader S&P 500 has declined 14.1%.

-Jaimy Lee

	

(END) Dow Jones Newswires

August 03, 2022 07:47 ET (11:47 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.